Tag Archive for: H. pylori testing

Stomach Cancer Screening | How Asian and Latinx Patients Can Self-Advocate

Stomach Cancer Screening | How Asian and Latinx Patients Can Self-Advocate from Patient Empowerment Network on Vimeo.

How can Asian and Latinx patients self-advocate for gastric cancer screening? Expert Dr. Joo Ha Hwang from Stanford Medicine shares advice for how patients can discuss gastric cancer screening with their provider and how providers should be engaging with patients for better care.

[ACT]IVATION TIP

“…especially if you come from Korea, Japan, where they actually have instituted national screening, with endoscopy, we actually have U.S. guidelines that state that if you come from a country whose guidelines state you should have endoscopy, then you should also have endoscopy, we should be following your home of origins guidelines for you and so, those patients should also have endoscopy.”

See More from [ACT]IVATED Gastric Cancer

Related Resources:

How Biomarkers Might Impact Future Stomach Cancer Care

How Biomarkers Might Impact Future Stomach Cancer Care

What Are Key Risk Factors for Stomach Cancer?

What Are Key Risk Factors for Stomach Cancer?

Potential Impact of Artificial Intelligence on Stomach Cancer Detection and CarePotential Impact of Artificial Intelligence on Stomach Cancer Detection and Care

Transcript:

Lisa Hatfield:

So in the United States, we do have many people from the Asian and Hispanic communities who may be at higher risk for gastric cancer, do you suggest that they talk to their provider about getting screened? And how might they phrase that question? Can I get screened for the H. pylorI? So if you had a patient who wanted to be screened or is interested in getting screened, how might they approach their provider in asking for the screening for gastric cancer or H. pylori?

Dr. Joo Ha Hwang:

I think the first step is to get tested for H. pylori, and pretty much, everyone who is, an immigrant to the U.S. is at much higher risk for having H. pylori, in the past, we used to say that the people from Asia, immigrants from Asia had an 80 percent risk of having H. pylori, from Mexico, it was more like around 60 percent, United States, it was in the 20 to 30 percent, it’s probably less than that now.

So worldwide, prevalence of H. pylori is certainly going down but again, providers should know this is something that is taught in medical school, is areas that are, endemic with H. pylori and providers should also know that, H. pylori is a carcinogen, and so if a patient just comes up in and says I’m worried about having H. pylori, I come from a high-risk population, it really shouldn’t be difficult to get tested for H. pylori, furthermore, if they have any symptoms, especially any epigastric pain what we call dyspepsia that should also trigger the provider to go ahead and test for H. pylori, because that’s part of the algorithm. So I think that all of these, it shouldn’t be difficult to engage a provider on that particular issue.

Lisa Hatfield:

So it is okay and appropriate for a patient to approach their provider and ask that question? So I appreciate that.

Dr. Joo Ha Hwang:

I think it’s important and I think that patients need to be their own advocates, because I have heard of instances where providers have been reluctant and in certain systems they’re discouraged from further testing, because it’s a capitated system. I think H. pylori testing is not that difficult, sometimes if patients want endoscopy, it can be, more challenging but again, especially if you come from Korea, Japan, where they actually have instituted national screening, with endoscopy, we actually have U.S. guidelines that state that if you come from a country whose guidelines state you should have endoscopy, then you should also have endoscopy, we should be following your home of origins guidelines for you and so, those patients should also have endoscopy.

But the challenge with that is that they’re going to end up paying for it, because it’s not typically covered by insurance or it’s not fully covered by insurance so you’d probably have to pay a copay, for something like that at this time.

Lisa Hatfield:

I have a friend who’s dealing with her father who lives in Korea, she’s from Korea, has been here about two, five years. He has stomach cancer. So we’ve been having this discussion, and that’s why I thought I’d ask that last question. She said she sometimes is afraid to approach her provider…

Dr. Joo Ha Hwang:

If you’re afraid to approach your provider, you need a different provider.

Lisa Hatfield:

Well, that’s a good suggestion too.

Dr. Joo Ha Hwang:

No, no. We’re supposed to work with you and listen to you and again, I go around and give a lot of talks to patient groups, and I like engaging in these types of activities, because I think the more information patients have, the more that they can talk with their physicians, and oftentimes patients know more than their physicians do, because they’ve done a lot more research. And hopefully you have a physician with some hubris who will listen to the patient and if they don’t know, they’ll kind of look things up, so yeah.

Lisa Hatfield:

Yeah. I appreciate that, thank you.

Dr. Joo Ha Hwang:

My pleasure.


Share Your Feedback

How Can Public Policy Measures Reduce Gastric Cancer in High-Risk Populations?

How Can Public Policy Measures Reduce Gastric Cancer in High-Risk Populations? from Patient Empowerment Network on Vimeo.

What are some ways that gastric cancer disparities can potentially be reduced by public policy actions? Expert Dr. Joo Ha Hwang from Stanford Medicine explains the significance of USPSTF recommendations, how these recommendations have helped in screening guidelines of other cancers, and proactive patient advice to help close the gastric cancer disparity gap. 

[ACT]IVATION Tip

“…I would encourage the listeners, especially if you have relationships with people in Congress, we need to reexamine making recommendations at a population level, and we really need to make recommendations based on individual risks, especially when we have clear-cut data as to who’s at high risk and what screening methods work.”

 

See More from [ACT]IVATED Gastric Cancer

Related Resources:

What Are the GAPS Study Key Findings About Gastric Precancer?

What Key Ways Is Early Detection of Stomach Cancer Delayed?

What Is the Role of Biomarker Testing in Stomach Cancer?

Transcript:

Lisa Hatfield:

Dr. Hwang, what public policy measures do you believe are crucial for reducing gastric cancer incidence and mortality, particularly in high-risk groups?

Dr. Joo Ha Hwang:  

So, there’s one key thing that really needs to happen. And that is there’s a body called the United States Preventative Services Task Force. They make all the guideline recommendations for screening. And what is important about a USPSTF guideline recommendation is that insurance companies are mandated to cover these screening tests at no cost. So, for example, breast cancer screening is part of this, colon cancer screening is part of the USPSTF recommendations.

So, what we really need is the USPSTF to recommend gastric cancer screening in high-risk populations. And there are clear high risk populations in the United States. And again, these are mainly immigrants from high-risk regions. But for example there’s a recent study out that showed that immigrants from Korea, Korean Americans have a 12-fold higher risk of developing gastric cancer than the baseline population.

And that risk is actually higher than the risk of colon cancer in the baseline population. And the biologic, the USPSTF already recommends colon cancer screening for that threshold and colon cancer screening is much, much more invasive than upper endoscopy because it requires a prep as well as doing the endoscopy. So, there are clearly high-risk groups out there. We’ve tried to engage the USPSTF to help make these recommendations, but it appears that the population at risk is too small.

And so they’re reluctant to make any recommendations for such a small population. The problem I have with that is we are entering an era of what we call precision medicine or personalized medicine. And that’s where we look at each individual, we don’t look at it on a population level. We look at each individual and determine what’s your risk for each individual cancer or disease? And let’s treat you for that.

And the approach that the USPSTF takes is still more of a population-based approach and not a precision-based approach. And the activation that I would encourage the listeners, especially if you have relationships with people in Congress, we need to reexamine making recommendations at a population level, and we really need to make recommendations based on individual risks, especially when we have clear-cut data as to who’s at high risk and what screening methods work.

And so this is a challenge for patients, especially the immigrant population who’s at high risk for developing gastric cancer. There are very weak screening recommendations, and it’s typically not covered by insurance. And so there’s a high cost to the patient, where this really should be some. It’s an effective screening method by doing endoscopy or even H. pylori testing that should be covered, because cost-effectiveness studies have been performed that show that this is cost-effective.


Share Your Feedback